Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide.
No risks detected for BVXP from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£39.75|
|52 Week High||UK£37.50|
|52 Week Low||UK£45.49|
|1 Month Change||-4.22%|
|3 Month Change||-1.24%|
|1 Year Change||0%|
|3 Year Change||25.00%|
|5 Year Change||253.33%|
|Change since IPO||1,938.46%|
Recent News & Updates
|BVXP||GB Biotechs||GB Market|
Return vs Industry: BVXP underperformed the UK Biotechs industry which returned 36.6% over the past year.
Return vs Market: BVXP underperformed the UK Market which returned 23.1% over the past year.
Stable Share Price: BVXP is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: BVXP's weekly volatility (3%) has been stable over the past year.
About the Company
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services.
Bioventix Fundamentals Summary
|BVXP fundamental statistics|
Is BVXP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BVXP income statement (TTM)|
|Cost of Revenue||UK£880.84k|
Last Reported Earnings
Dec 31, 2020
Next Earnings Date
|Earnings per share (EPS)||1.32|
|Net Profit Margin||66.22%|
How did BVXP perform over the long term?See historical performance and comparison
3.5%Current Dividend Yield
Is Bioventix undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: BVXP (£39.75) is trading above our estimate of fair value (£26.72)
Significantly Below Fair Value: BVXP is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BVXP is poor value based on its PE Ratio (30.1x) compared to the European Biotechs industry average (24.9x).
PE vs Market: BVXP is poor value based on its PE Ratio (30.1x) compared to the UK market (23.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BVXP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BVXP is overvalued based on its PB Ratio (20.1x) compared to the GB Biotechs industry average (5.8x).
How is Bioventix forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bioventix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Bioventix performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BVXP has high quality earnings.
Growing Profit Margin: BVXP's current net profit margins (66.2%) are higher than last year (65.3%).
Past Earnings Growth Analysis
Earnings Trend: BVXP's earnings have grown by 14.8% per year over the past 5 years.
Accelerating Growth: BVXP's earnings growth over the past year (5%) is below its 5-year average (14.8% per year).
Earnings vs Industry: BVXP earnings growth over the past year (5%) underperformed the Biotechs industry 19.9%.
Return on Equity
High ROE: BVXP's Return on Equity (66.7%) is considered outstanding.
How is Bioventix's financial position?
Financial Position Analysis
Short Term Liabilities: BVXP's short term assets (£9.8M) exceed its short term liabilities (£839.8K).
Long Term Liabilities: BVXP's short term assets (£9.8M) exceed its long term liabilities (£58.1K).
Debt to Equity History and Analysis
Debt Level: BVXP is debt free.
Reducing Debt: BVXP has not had any debt for past 5 years.
Debt Coverage: BVXP has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: BVXP has no debt, therefore coverage of interest payments is not a concern.
What is Bioventix current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BVXP's dividend (3.55%) is higher than the bottom 25% of dividend payers in the UK market (1.36%).
High Dividend: BVXP's dividend (3.55%) is low compared to the top 25% of dividend payers in the UK market (3.95%).
Stability and Growth of Payments
Stable Dividend: BVXP's dividends per share have been stable in the past 10 years.
Growing Dividend: BVXP's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (71.9%), BVXP's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Peter Harrison (63 yo)
Mr. Peter John Harrison, MA, serves as the Chief Executive Officer of Bioventix PLC. Mr. Harrison has worked in the field of antibody technology since 1986 and has extensive experience of the development a...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD391.08K) is below average for companies of similar size in the UK market ($USD565.86K).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
Experienced Board: BVXP's board of directors are considered experienced (7.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Bioventix PLC's employee growth, exchange listings and data sources
- Name: Bioventix PLC
- Ticker: BVXP
- Exchange: AIM
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£207.071m
- Shares outstanding: 5.21m
- Website: https://www.bioventix.com
Number of Employees
- Bioventix PLC
- 27-28 Eastcastle Street
- Greater London
- W1W 8DH
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 21:40|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.